# US 2019/0316210 A1 · Methods and nucleic acids for analyses of cellular proliferative disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0316210 A1
- Document ID: US20190316210A1
- Status: Published application
- Kind: A1
- Application number: 16/453,688
- Filed: 2019-06-26
- Published: 2019-10-17
- Earliest claimed: 2005-04-15
- Assignees: Epigenomics AG
- Applicants: Epigenomics AG
- Inventors: Catherine E. Lofton-Day; Andrew Z. Sledziewski; Ralf Lesche; Matthias Schuster; Juergen Distler; Reimo Tetzner; Thomas Hildmann; Fabian Model; Xiaoling Song
- Web page: https://patentgrep.com/patent/US20190316210A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/112: Disease subtyping, staging or classification
- C12Q 2600/154: Methylation markers
- C12Q 2600/158: Expression markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The invention provides methods, nucleic acids and kits for detecting, or for detecting and distinguishing between or among liver cell proliferative disorders or for detecting, or for detecting and distinguishing between or among colorectal cell proliferative disorders. The invention discloses genomic sequences the methylation patterns of which have utility for the improved detection of and differentiation between said class of disorders, thereby enabling the improved diagnosis and treatment of patients.

## Claims

### Claim at position 1

1-31. (canceled)

### Claim 32

A method for detecting CpG dinucleotide methylation in genomic DNA of the Septin 9 gene from colorectal cells, comprising:
a) extracting or otherwise isolating genomic DNA comprising colorectal cell genomic DNA comprising a Septin 9 gene from a biological sample obtained from a subject;
b) treating the genomic DNA of a), or a fragment thereof comprising the Septin 9 gene, with one or more reagents to convert cytosine bases that are unmethylated in the 5-position thereof to uracil or to another base that is detectably dissimilar to cytosine in terms of hybridization properties;
c) contacting the treated genomic DNA of b), or the treated fragment thereof, with an amplification enzyme and at least one oligonucleotide or peptide nucleic acid (PNA) oligomer comprising a contiguous sequence of at least 9 nucleotides that is identical to, complementary to, or hybridizes under moderately stringent or stringent conditions to a sequence selected from the group consisting of SEQ ID NOs: 4 to 15, and the complements thereof, wherein the treated colorectal cell genomic DNA or the fragment thereof is amplified to produce at least one amplificate, and
d) detecting by determining a presence of, or a property of, the at least one amplificate, the methylation state or level of at least one CpG dinucleotide of the Septin 9 gene, or an average, or a value reflecting an average methylation state or level of a plurality of CpG dinucleotides of the Septin 9 gene.

### Claim 33 (depends on 32)

The method of claim 32, wherein the at least one oligonucleotide or peptide nucleic acid (PNA) oligomer of step c) is not identical or complementary to all or a portion of the sequences according to SEQ ID NOs: 1 to 3.

### Claim 34 (depends on 32)

The method of claim 32, wherein the biological sample obtained from the subject is selected from the group consisting of cell lines, histological slides, biopsies, paraffin-embedded tissue, body fluids, urine, blood plasma, blood serum, whole blood, cells isolated from the blood, and combinations thereof.

### Claim 35 (depends on 32)

The method of claim 32, wherein treating the genomic DNA, or the fragment thereof in step b) comprises use of a reagent selected from the group consisting of bisulfite, hydrogen sulfite, disulfite, and combinations thereof.

### Claim 36 (depends on 32)

The method of claim 32, wherein the at least one oligonucleotide or peptide nucleic acid (PNA) oligomer of step c) is a methylation-unspecific primer.

### Claim 37 (depends on 32)

The method of claim 32, wherein determining of step d) comprises the use of at least one nucleic acid molecule or peptide nucleic acid molecule, in each case the at least one nucleic acid molecule or peptide nucleic acid molecule comprising a contiguous sequence of at least 9 nucleotides in length that is identical to, complementary to, or hybridizes under moderately stringent or stringent conditions to, a sequence selected from the group consisting of SEQ ID NOs: 4 to 15, and complements thereof, wherein the at least one nucleic acid molecule or peptide nucleic acid molecule suppresses amplification of the nucleic acid to which it is hybridized.

### Claim 38 (depends on 32)

The method of claim 32, wherein determining in step d) comprises hybridization of at least one nucleic acid molecule or peptide nucleic acid molecule, in each case the at least one nucleic acid molecule or peptide nucleic acid molecule comprising a contiguous sequence of at least 9 nucleotides in length that is identical to, complementary to, or hybridizes under moderately stringent or stringent conditions to, a sequence selected from the group consisting of SEQ ID NOs: 4 to 15, and complements thereof.

### Claim 39 (depends on 32)

The method of claim 32, wherein the at least one hybridizing nucleic acid molecule or peptide nucleic acid molecule is bound to a solid phase.

### Claim 40 (depends on 39)

The method of claim 39, further comprising extending the at least one hybridized nucleic acid molecule or peptide nucleic acid molecule by at least one nucleotide base.

### Claim 41 (depends on 32)

The method of claim 32, wherein determining in step d), comprises sequencing of the amplificate.

### Claim 42 (depends on 32)

The method of claim 32, wherein the oligonucleotide or peptide nucleic acid (PNA) oligomer of step c) is a methylation-specific primer.

### Claim 43 (depends on 32)

The method of claim 32, wherein the contacting of step c) comprises use of at least one method selected from the group consisting of: use of a heat-resistant DNA polymerase as the amplification enzyme; use of a polymerase lacking 5′-3′ exonuclease activity; use of a polymerase chain reaction (PCR); and generation of an amplificate nucleic acid molecule carrying a detectable label.

### Claim 44 (depends on 32)

The method of claim 32, wherein the subject has colorectal cancer or a colorectal cell proliferative disorder and the method is carried out repeatedly.

### Claim 45 (depends on 32)

The method of claim 32, wherein the subject has colorectal cancer or a colorectal cell proliferative disorder.

### Claim 46 (depends on 45)

The method of claim 45, wherein the subject has a neoplastic colorectal cell proliferative disorder.

### Claim 47 (depends on 32)

A kit for carrying out the method of claim 32, the kit comprising at least two oligonucleotides or peptide nucleic acid (PNA) oligomers each comprising a contiguous sequence of at least 9 nucleotides that is identical to, complementary to, or hybridizes under moderately stringent or stringent conditions to a sequence selected from the group consisting of SEQ ID NOs: 4 to 15, and the complements thereof.
